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1129-199 Predictors of Adverse Events Complicating Carotid 
Artery Stenting in the Era of Distal Protection Devices 
Ramtin Aaah. Leslie Cho, Jacob Schneider, Albert W. Ghan. Marco Roffi, Christopher T. 
Bajzer, Jay S. Yadav, The Cleveland Clinic Foundation, Cleveland, OH 
Introduction: Despite the rapid acceptance of carotid stenting(CS) as an alternative to 
endarterectomy. little is known about clinical and angiographic predictors of poor out- 
come with CS in the current era. Methods: Using the data from our registry of 351 con- 
secutive patients who underwent CS between 1998 and 2001, we looked at 40 different 
clinical and angiographic variables to assess potential predictors of adverse events(AE). 
Majority of the patients in our registry had distal emboli protection devices used in con- 
junction with CS. Adverse events was defined as a combined endpoint of myccardial inf- 
arction, stroke, and death. Using multi-variate analysis, the predictors of AE peri- 
procedurally and at 6 months are shown. Resultsz The most significant predictors of 
peri-procedural AE were histoly of stroke, transient ischemic attack(TlA) and need for 
open heart surgery(pre-OHS). Also patients with COPD were at higher risk of events in 
our analysis. We found no association between patient’s age, lesion characteristics (cal- 
cification, morphology or diameter), contra-lateral carotid stenosis/occlusion and AE. At 6 
months, the predictors of poor outcome were low cardiac ejection fraction and diabetes. 
Conclusions: In the current era, patients who undergo CS with symptomatic lesions or 
are pm-OHS have higher peri-procedural AE; beyond the procedural period the tradi- 
tional risk factor for cardiovascular events, diabetes and low ejection fraction become 
more important predictor of events. 
Time-point Predictor P-value 
Peri-procedural Histoly of Stroke 0.0041 
History of TIA 0.049 
Pm-OHS 0.010 
6.months 
History of COPD 0.030 
Diabetes 0.048 
Baseline EF<30% 0.016 
1129-200 Chronic VisceraVMesenteric Ischemia: Role of 
Percutaneous Angioplasty and Stenting in Cellac and 
Mesenteric Artery Disease 
David E. Allie, Mitchell D. Lirtzman, Charles H. Wyatt, V. Antoine Keller, Mohamed H. 
Khan, Muhammad A. Khan, Peter S. Fail, Chris J. Hebert, Adam A. Allie, Craig M. 
Walker, Cardiovascular Institute of the South, Lafayette, LA, Columbia Medical Canter of 
Southwest Louisiana, Lafayette, LA 
Backaround: Surgical treatment for chronic mesenteric ischemia (CMI) is effective but 
technically demanding with operative mortality ranges from 3-14.7% (mean=7.5%) and 
morbidity ranges from E-44.7% (mean=28%). Percutaneolis transluminal angioplasty 
(PTA) alone for CMI is reported but has excessive recurrence rates (12.60%; 
mean=26%). Sparse data exists regarding indications, safety, feasibility, and durability of 
PTAlstenting for celiac and mesenteric artery disease. 
Methods: Between January 1998July 2002, 68 visceral artery stenosis [42 superior 
mesenteric (SMA) and 26 celiac artery (CA)] underwent PTAIstenting in 45 patients with 
CMI. A multivariable retrospective chart review was performed. Abdominal pain and 
weight loss wsre present in 41/45 (91%) and 39/45 (87%) respectively. An 8-French 
transfemoral approach was used in 30/42 (71%) SMA and 21/26 (80%) CA. A transbra- 
chial approach was required in 12/42 (29%) SMA and 5/20 (20%) CA. All patients 
received balloon expandable stems. 30168 (44%) vessels had 6 month duplex ultrasound 
(DU) and 25/88 (36%) angiography at median follow up of 23 months (range 7-54 
months). 
Results: Procedural success 67168 (98.5%) with 6 requiring a change from femoral to 
brachial access. No bowel infarction, stent thrombosis, or procedural deaths occurred. 
Pain relief improved in 38/42 (92%) and weight gain in 35139 (90%). 3/55 (5.4%) avail- 
able for objective follow-up developed restenosis (DU 2130 (6.6%) and angiography l/25 
(5%)] requiring repeat PTA/stenting for 100% primary assisted mid-term clinical succsss. 
There were no major complications requiring surgery and 2 minor access site hemato- 
mas (< 2 cm). 30.day mortality 0%. No late bowel related deaths. The l-year and P-year 
symptom free survival rates were 97.5% and 89.5% respectively. 
Conclusion: PTA/stenting for SMA and CA disease is a safe and effective treatment 
option for CMI offering excellent immediate and mid-term clinical succsss. 
1129-201 Bivalirudin as Sole Anticoagulant in Peripheral Vascular 
Disease: A Safety and Feasible Alternative in Renal and 
iliac Interventions 
David E. Allie, Mitchell D. Lirtzman, Charles H. Wyatt, V. Antoine Keller, Mohamed H. 
Khan, Muhammad A. Khan, Peter S. Fail, Chris J. Hebert, Adam A. Allie, Craig M. 
Walker, Cardiovascular Institute of the South, Lafayette, LA, Columbia Medical Center of 
Southwest Louisiana. Lafayette, LA 
Backaround: Many heparin limitations are Overcome by the direct thrombin inhibitor 
bivalirudin (Angiomax, The Medicines Company, Parsippany, NJ). Bivalirudin has shown 
a reduced incidence of ischemic and bleeding complications post percutaneous coronary 
interventions. The pharmacokinetic profile of bivalirudin appears well suited for percuta- 
neous peripheral intervention (PPf) yet few data exist regarding safety and feasibility in 
this setting. 
Methods: 180 renal and 75iliac PPl’s ware performed (May 2001-June 2002) with biva- 
lirudin as anticoagulation and compared to a historical heparin control (HC). Angiomax 
dose: 0.75 mglkg bolus with 1.75 mglkglhr infusion for procedural duration. Variables: 
Sheath removal time (SRT), access complication (AC), time to ambulate (TA), and length 
of stay (LOS). Follow up: 6 month renal and iliac duplex ultrasound. 
Rssultg No thrombotic events, intracranial bleeding, or major surgical complications 
occurred in bivalirudin group (BG). SRT, TA and LOS were reduced compared to HC 
(Table). 7/180 (3.8%) renal and 31’75 (4%) iliac required repeat PPI. 
Conclusion: Bivalirudin is a safe and feasible alternative anticoagulant in renal and iliac 
PPI and may offer decreased SRT, TA and LOS. Larger prospective randomized trials 
are warranted. 
Table 
Variables Ki 
Renal, 
I-l=180 
PPI success, ” 180 (100) 
(%) 
AC (Majorl), n 2(1.1) 
(%) 
AC (MinoR), 5(2.7) 
ll(%) 
SRT ~60 min, n 152 (84) 
(%) 
SRT >60 min, n 28 (16) 
(“@ 
LOS ~24 hrs, n 154(85.5) 
(%) 
LOS >24 hrs, ” 26(14.5) 
(%) 
TA <8 hrs, ” (“‘%) 136(75.5) 
TA >6 hrs, n (%) 44(24.5) 75 (42) 
HC Renal, 
n=l80 
179 (99) 
6 (3.3) 
8 (4.4) 
106 (59) 
74 (41) 
130 (72) 
50 (28) 
105 (58) 
P- Bc. HC Iliac 
VEdW Iliac n=75 
n=75 
0.3173 75 (100) 74 (98.6) 
0.1532 2(2.5) 3 (4) 
0.3974 3(4) 5 (6.6) 
<O.OOO 36 (48) 21 (28) 
1 
~0.000 39 (52) 54 (72) 
1 
0.002 42(56) 32 (43) 
0.002 33(44) 43(57) 
0.0005 31(41) 19 (25) 
0.0005 44(59) 56 (75) 
P- 
value 
0.317 
3 
0.650 
3 
0.468 
9 
0.011 
9 
0.011 
9 
0.103 
6 
0.103 
6 
0.038 
3 
0.038 
3 
l=“Major’ = any surgery, > 5 cm hematoma, or > 2u transfusion 
P=‘Minor’ = all other non-intracranial or retroperitoneal bleeding 
1129-202 Is Bivalirudin a Safe Alternative to Heparin During 
Carotid Stenting? A Case Matched Study 
Yuliva G. Adamvan, Gishel New, Sriram lyer, Thosaphol Limpijankit, Christina Brennan, 
Milena G. Adamian, Roxana Mehran, lzat Hjazi. Zoran Lasic, Sheriff Ibrahim, Jiri J. Vitek, 
Gary S. Roubin, Cardiovascular Research Foundation, New York, NY, Lenox Hill Heart 
and Vascular Institute, New York, NY 
Backaround: Previous studies have shown safetv and feasibilitv of the direct thrombin 
inhibitor Bivalirudin (B) during percutaneous coronary interventions. However, the safety 
txofile of this aaent as an alternative to unfractionated Heoann (UFH) durina carotid 
stenting (CS) is not known. 
_ 
Methods: From December 2001 to September 2002,59 consecutive pts (mean age = 72 
+ 9 yrs, 80.4% male) underwent CS with B and compared to 83 case matched controls 
receiving UFH during the same timeframe. B was administered in bolus dose of 0.75mgl 
kg, followed by drip (1.75 mg/kg/hr) throughout the procedure. 5,000 units of UFH were 
administered prior to the procedure in the UFH group. No GP Ilb/llla inhibitors were 
used. Neurological events, bleeding and vascular complications were recorded and adju- 
dicated by an independent committee. 
Results: Closure devices were used more often in B group than in UFH group (76.3% 
vs. 28.9% respectively, p< 0.0001). In-Hospital neurologic and vascular complications 
are shown in table. 
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Clinical Outcomes BE59 UFH.83 P value 
Death , n% 0 (/59) 0 (O/83) NS 
Major Stroke, n% 0 (O/59) 1.2 (l/83) 1 .oo 
Minor stroke, n% 0 (O/59) 0 (O/83) NS 
Hematoma > 5cm (%) 1.7 (l/59) 3.6(3/83) 0.64 
Pseudoaneurysm 0 (O/59) 2.4 (2/83) 0.51 
Transfusion (%) 0 (O/59) 8.6 (7/81) 0.02 
Vascular Complication 1.7 (1159) 4.9 (4/81) 0.39 
Conclusion: The use of B during carotid stenting is feasible, safe and may be an attrac- 
tive alternative to UFH in view of lower vascular complications without an increase of 
neurologic events. 
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Featured Oral Session...Drug-Eluting 
Stents in High-Risk Populations 
Tuesday, April 01, 2003, 8:30 a.m.-10:OO a.m. 
McCormick Place, Room S403 
8:45 a.m. 
839FO-2 Sirolimus-Eluting Stents in Bifurcation Lesions: Six- 
Month Angiographic Results According to the 
Implantation Technique 
Antonio Colombo, Yves Louvard. Cherukupalli Raghu, Carlo Di Mario, Josef Ludwig, 
Mariin Leon, Jeffrey Moses, Mark-Claude Morice. Egon Wulferl, David Holmes, lnstitut 
Cardiovasculaire Paris Sud, Massy. France, Centro Cuore Columbus, Milan, Italy 
Background. Sirolimus-eluting stents have been associated with a near complete aboli- 
tion of the restenosis process. In the era of drug-eluting stents, the technical approach to 
bifurcation lesions is crucial. 
Methods. A randomized study was set up to assess the results of the CYPHER stent 
(Sirolimus-eluting stent) in the treatment of bifurcation lesions. Patients were randomized 
to receive a CYPHER stent in the main branch with provisional stenting in the side 
branch or systematic stenting of both branches with 2 CYPHER stents. The technique 
applied was left to the operator’s judgment. 
Results. From June 2001 to April 2002,86 patients were enrolled in 5 centers. The pop- 
ulation consisted of 80% male pts, mean age 63*10 y, 22% diabetic. To date 47 tines 
views of the acute phase and 6.month follow-up have been analyzed. 3 different tech- 
niques were used: 1) stent in main branch only, followed by kissing balloon, 2) T stenting 
with kissing balloon, 3) modified Y stenting. Restenosis rate defined as stenosis at follow- 
up 2 50% in the main or side branch is shown in the table below: 
Conclusion. Use of Sirolimus-eluting stents to treat bifurcation lesions is an eflective 
technique and reduces restenosis as compared to earlier results with other stents. Stent- 
ing of the main branch, followed by kissing balloon inflation should be the preferred tech- 
nique whenever possible as it seems to provide the most favorable results. 
Technique 12 3 
Patients (n) 13 13 16 
Restenosls in side branch (n) 1 3 3 
Restenosis in main branch (n) 0 0 1 
Restenosis in both branches (n) 0 1 1 
Restenosis rate (%) 7 30.8 31.2 
9:00 a.m. 
839FO-3 Bifurcational Coronary Artery Lesion Treatment With 
Rapamicine-Eluting Stents: Results From a Single 
Center Experience 
Flavio Airoldi Vassilis Spanos, Goran Stankovic, Carlo Di Mario, Alaide Chieffo, Carlo -I 
Briguori, Francesco Liistro, Mauro Carlino, Maneo Montorfano, Massimo Ferraro, 
Antonio Colombo, Emo Centro Cuore, Milan, Italy. San Raffaele Hospital, Milan, Italy 
Methods we report the immediate and mid term results in a series of 79 consecutive 
bifurcational lesions (BL) treated with rapamtcine eluting stems (Cypher, Cordis, J &J, 
Miami, FI). Lesions were located as follows: 41 on LAD-diagonal branch; 1 on LAD-sep- 
tal; 25 On LCX-obtuse marginal; 10 on RCA; 2 on LM-LCX-LAD. Result: Angioplasty with 
only one stent on the main branch was performed in 23% of lesions; in the remaining 
77% Of BL, both branches were stented with the modified T-stenting technique. Ilb-llla 
receptor antagonists were used in 25% of the cases. Technical success was reached in 
all cases. During the hospital stay no death neither urgent target vessel revascularization 
occurred; 5 non-Q myocardial infarction (6.3%) were recorded. After the procedure all 
the patients were treated with double antiplatelet therapy for at least 3 months. During 
the first month, one patient died. All the eligible patients (n=24) underwent a B-months 
angiographic follow-up as reported in table. Binary restenosis (~50%) occurred in 2 BL 
(8%) and TVR was performed in 2 cases (4%). The complete clinical and angiographic 
follow-up will be available for the time of presentation. Conclusion BL stenting with 
rapamicine eluting stems is associated to a high rate of technical success. One month 
follow-up has showed a low incidence of subacute thrombosis. Preliminary angiographic 
follow-up data indicate a low rate of restenosis. However, the definitive judgment of this 
treatment must be confirmed at the end of the follow-up. 
p=O.Ol for paired t-test comparisons to baseline values 
Basal ref., mm Basal MLD, mm Post MLD, mm FU MLD, mm 
Main branch 2.81*0.39 0.88*0.41 2.79+0.44’ 2.56t0.61’ 
Side brach 2.08ztO.38 0.9liO.45 2.29+0.41’ 1.85r0.78 
9:15 a.m. 
839FO-4 Sirolimus-Eluting Stents for Treatment of In-Stent 
Restenosis in the Real World: Preliminary Results From 
the Rapamycin-Eluting Stent Evaluated at Rotterdam 
Cardiology Hospital (RESEARCH) Registry 
Francesco Saia, Pedro A. Lemos, Muzaffer Degertekin, Evelyn Regar, Chourmouzios A. 
Arampatzis, Chi-Hang Lee, Kengo Tanabe, Pim de Feyter. Willem J. van der Giessen. 
George Sianos, Pieter Smits, Ron T. van Domburg, Patrick W. Serruys, Erasmus MC, 
Thoraxcenter, Rotterdam, The Netherlands 
Background: In-stent restenosis (ISR) represents a significant clinical problem following 
stent implantation. Brachytherapy is to date the only effective treatment, but it is not free 
from drawbacks and presents a not neglegible number of failures. Preliminary studies 
have shown that sirolimus-eluting stents @ES) are safe and effective for treatment of 
ISR. We are testing the efficacy of this strategy in daily practice. 
Methods: Since 16th April 2002 all patients undergoing a PTCA at our institution have 
been treated with SE.?, irrespective of clinical presentation and lesion morphology, and 
enrolled in the RESEARCH registry. Exclusion criteria included participation to another 
trial or unavailability of an adequately sized SES. The Registry will be closed on the 15th 
of October 2002. All patients will receive 6 and 1 P-month clinical follow-up as well as a 6. 
month angiography. Cost-effectiveness will be compared to the historical cohort of 
patients treated in the preceding six months. 
Results: After 4 months from the beoinnino of the studv. 382 oatlents had at least one , 
SES implanted (76.7% of all PTCA patients-in the period). Among them, 37 (9.7%) were 
treated for ISR 140 les~onsl. Clinical oresentation was stable anoina for 28 (75.6%) 
patients, unstable angina fo; 8 (21.6%; and acute MI for 1 (2.7%).“23 patients {62.2%j 
had multi-vessel disease. Target vessel was kfl anterior descending in 14 cases (35%), 
circumflex in 8 (20%), right coronary in 11 (27.5%), left main in 3 (7.5%), and CABG in 4 
(10%). Lesions were classified as focal (11, 27.5%), diffuse (9, 22.5%), proliferative (12, 
30%) and totally occlusive (8, 20%). Five patients (18.5%) had been previously treated 
with brachytherapy. A total of 66 SES were implanted (average 1.78ipatient). of which 9 
(13.6%) equal or less than 2.5 mm in diameter. Average stent lenght per patient was 
31.82 23.1 mm (median 26 mm; range 8-92 mm). All patients received clopidogrel for a 
minimum of two months. Procedural success was achieved in 36137 patients (97.3%). 
Conclusions: We are evaluating the effectiveness of SES to treat ISR. Procedural 
results are satisfactory. Short- and medium-term clinical and angiographic follow-up is 
needed lo draw further conclusions. 
9:30 a.m. 
839FO-5 Treatment of In-Stent Restenosis Using Sirolimus- 
Eluting Stents: ISR II Registry 
Philippe Commeau Paul T. Barragan, Pierre 0. Roquebert, Jean L. Bouvier, Bertrand 
Comet, Gilles Macaluso, CHP Beauregard, Marseille, France 
In-Stent Restenosis (ISR) remains the major limitation of percutaneous coronary inter- 
vention. The efficacy of Sirolimus-eluting (SE) stent for treatment of ISR is still under 
evaluation. 
Twenty three patients (pts) (mean age : 64.0 * 11 .l yrs) with 34 ISR lesions (mean 1.6 * 
0.7 lesion per patient) in native coronary arteries were treated with 8 or 18mm SE stents 
(mean stent length 19.0 * 9.5 mm). Sixteen pts were male, 7 diabetic, 20 treated for 
hypercholesterolemia and 5 were in unstable angina. Forty eight stents were success- 
fully implanted ( 39% RCA, 33% LAD, 28 % LCX) at 16.1 * 3.2 bars. Procedural QCA 
indicated a reference vessel diameter of 2.7 + 0.7 mm. a minimum lumen diameter of 0.8 
f 0.3 mm pre-stent and 2.5 + 0.6 mm post-stent. All patients received Clopidogrel (75mg 
x 2 daily) or Ticlopidine (250mg x 2 daily) for 2 months. One month adverse events 
included 2 non-Q myocardial infarctions : one in-hospital unrelated with the stented 
artery and another due to a subacute thrombotic occlusion of the SE stem at 5 days. 
Repeat angiography will be performed 8 months after the baseline procedure. 
Conclusions : This preliminary ISR II registry shows an early feasibility for the use of SE 
stent to treat ISR. Eight month clinical and angiographic follow-up will be reported in 
March 2003. 
